A股異動 | 績後獲券商唱好 萬泰生物(603392.SH)連續第2日大漲
格隆匯2月16日丨昨日漲停的萬泰生物(603392.SH)再度漲6.4%,報241.3元,暫成交4.28億元,總市值1464億元。公司2021年淨利20.16億元,同比大幅增長197.83%。主要是二價宮頸癌疫苗、試劑及活性原料收入增加所致。華西證券點評稱,公司業績超預期,國內HPV疫苗市場規模遠未到達峯值,堅定看好公司二價HPV疫苗放量增長,維持其“買入”評級;信達證券指出,公司HPV疫苗產銷同增,業績超預期增長。公司在研項目進展順利,將逐步進入收穫期,產品上市有望顯著增厚公司業績。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.